H.C. Wainwright analyst Ed Arce maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report) today and set a price target of $45.00. The company’s shares closed last Tuesday at $13.10, close to its 52-week low of $11.91.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.4% and a 38.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals.
Pliant Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $39.33.
See Insiders’ Hot Stocks on TipRanks >>
Pliant Therapeutics’ market cap is currently $472.1M and has a P/E ratio of -5.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
Read More on PLRX:
